OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director received an award of 151 CYTK shares | OQRO

Home
Insider trades
Cytokinetics
Director received an award of 151 CYTK shares

Insider trades

Insider trade

Director received an award of 151 CYTK shares

Traded Jul 15, 2026 · Filed Jul 16, 2026

CYTCytokineticsCYTK

151
Shares · @ $82.62

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jul 15, 2026
Reporting period: Not applicable
Filed with the SEC: Jul 16, 2026

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-26-000078
Filed / recorded

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Jul 16, 2026, 8:28 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

James M Daly

Relationship

Director

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Jul 15, 2026

Transaction code

Shares / units

151

Price per share

$82.62

Acquired / disposed

Acquired (A)

Shares owned after

3,390

Ownership form

Direct

Amendment

Footnotes from the filing

Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

Around the same time

Robert I BlumPresident & CEO

Filed 8w ago

7,500Shares · @ $10.60

Traded Aug 10 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Robert I Blum (President & CEO) sold ~$576K of Cytokinetics

Automatic saleFiled 8w ago

Robert I BlumPresident & CEO

Filed 8w ago

7,500Derivative units

Traded Aug 10 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record